UNSPSC 51392702: Acefylline piperazine

This classification denotes a bronchodilator with the molecular formula 2C9H10N4O4.C4H10N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 12I91IOS6Z chemically known as 2-(1,3-dimethyl-2,6-dioxopurin-7-yl)acetic acid;piperazine but generally known as acefylline, which bears US NIH Compound Identifier 87819. European Medicines Agency schedules Acefylline piperazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12706MIG.

UNSPSC 51392702 Acefylline piperazine is a Commodity code, but the recent state and local opportunities tagged under it diverge sharply from its nominal pharmaceutical scope. The opportunities show procurement of naloxone (an opioid antagonist), drug deactivation systems, and pharmacy benefit program infrastructure — none of which match acefylline piperazine, a respiratory bronchodilator. The code shows little relevant recent activity aligned with its actual chemical definition. State and local issuers tagging unrelated pharmaceutical products and services under this code suggest either data-quality issues in the source system or inconsistent coding practice at the issuing agencies, making the code an unreliable signal for vendors in pharmaceutical supply chains.

Activity under this code is sparse and geographically limited. The two recent records span Florida (Seminole County's IFB for naloxone and drug deactivation systems, due July 26, 2023) and Texas (the Texas Health and Human Services Commission's RFI on direct-to-manufacturer pharmacy programs, posted April 3, 2026). The Seminole County procurement is a straightforward goods purchase with annual volume commitments and quarterly delivery schedules; the Texas RFI is exploratory market intelligence with no award value or binding timeline. Issuing bodies are a county health department and a state health agency. The code presents minimal current pursuit opportunity unless your firm operates in naloxone supply or pharmacy benefit administration — and even then, the coding mismatch suggests opportunities in this space may be tagged under other codes with greater consistency and search visibility.